The MIND-TD Faculty have been compensated by Neurocrine Biosciences, Inc.
By continuing to use this site, you agree to our use of cookies as described in our Cookie Policy.
This site contains information intended only for US healthcare professionals involved in the management of people with tardive dyskinesia. This website is part of a disease-awareness, non-CME program sponsored by Neurocrine Biosciences, Inc., and hosted by Current Psychiatry.
The MIND-TD Faculty have been compensated by Neurocrine Biosciences, Inc.
The MIND-TD Faculty have been compensated by Neurocrine Biosciences, Inc.
Question: According to the American Psychiatric Association, when should you use a structured instrument, such as the AIMS, to assess patients at risk for tardive dyskinesia? Select all that apply.